CoChat
Sign Up
Cited by 128Substance Abuse Treatment and OutcomesOpioid Use Disorder TreatmentYouth, Drugs, and Violence

Psychopathology in methamphetamine-dependent adults 3 years after treatment

Open access
GLASNER‐EDWARDS, SUZETTE, MOONEY, LARISSA J., MARINELLI‐CASEY, PATRICIA, HILLHOUSE, MAUREEN, ANG, ALFONSO, RAWSON, RICHARD A., THE METHAMPHETAMINE TREATMENT PROJECT CORPORATE AUTHORS·2010·Drug and Alcohol Review
DOI 10.1111/j.1465-3362.2009.00081.xPMC PMC3772133
Open this paper in CoChat — free account

Abstract

INTRODUCTION AND AIMS: Although psychiatric symptoms are frequently observed in methamphetamine (MA) users, little is known about the prevalence of psychiatric disorders in MA-dependent individuals. This is the first study to examine the association of psychiatric disorders with substance use and psychosocial functioning in a large sample of MA users 3 years after treatment. We predicted that psychiatric diagnoses and severity would be associated with substance use and poorer overall functioning over the 3 year post-treatment course. DESIGN AND METHODS: Participants (N = 526) received psychosocial treatment for MA dependence as part of the Methamphetamine Treatment Project and were reassessed for psychosocial functioning and substance use at a mean of 3 years after treatment initiation. DSM-IV psychiatric diagnoses were assessed at follow-up using the Mini-International Neuropsychiatric Interview. Psychosocial functioning was assessed using the Addiction Severity Index. RESULTS: Overall, 48.1% of the sample met criteria for a current or past psychiatric disorder other than a substance use disorder. Consistent with prior reports from clinical samples of cocaine users, this rate was largely accounted for by mood disorders, anxiety disorders and antisocial personality. Those with an Axis I psychiatric disorder evidenced increased MA use and greater functional impairment over time relative to those without a psychiatric disorder. DISCUSSION AND CONCLUSIONS: This initial investigation of psychiatric diagnoses in MA users after treatment indicates elevated rates of Axis I and II disorders in this population and underscores the need for integrated psychiatric assessment and intervention in drug abuse treatment settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1465-3362.2009.00081.x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • People who experience depressive symptoms and use methamphetamine may have a poorer prognosis for both conditions and may experience worse treatment outcomes.

    “Glasner-Edwards et al 18 identified that people who experience depressive symptoms and use MA may have a poorer prognosis for both conditions and may experience worse treatment outcomes.”

    From Protocol for a systematic review of psychological treatment for methamphetamine use: An analysis of methamphetamine use and mental health symptom outcomes (2017) · cites this paper as [18]

    The Results sections report more frequent methamphetamine use among participants with mood disorders and greater drug and psychiatric problem severity over time among those with an Axis I diagnosis. These findings support concern about poorer outcomes, but the study did not isolate depressive symptoms or establish a poorer prognosis for both conditions specifically. The Limitations section says the effects of pre-existing diagnoses on treatment outcomes are unknown. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 35 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [18]Zweben JE Cohen JB Christian D Psychiatric symptoms in methamphetamine users Am J Addict 2004 13 181 90 15204668

Cited by

Sorted by citations

Related

Authors
GLASNER‐EDWARDS, S., MOONEY, L. J., MARINELLI‐CASEY, P., HILLHOUSE, M., ANG, A., RAWSON, R. A., & THE METHAMPHETAMINE TREATMENT PROJECT CORPORATE AUTHORS
Affiliations
University of California, Los Angeles (US)
ORCID
Venue
Drug and Alcohol Review
Publisher
Wiley
Published
2010-01
Volume
29
Issue
1
Pages
12-20
ISSN
  • 0959-5236 (ISSN-L)
  • 1465-3362
DOI
10.1111/j.1465-3362.2009.00081.x
PMC
PMC3772133
OpenAlex
W1941604713
Cited by
128
References
35
Citations by year
2026: 6 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 32 · 2019: 2 · 2018: 9 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 12 · 2013: 9 · 2012: 7
FWCI
6.05
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Drug and Alcohol Review (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (K23DA020085)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Social Sciences › Demography › Youth, Drugs, and Violence
Keywords
methamphetamine dependence, psychiatric comorbidity, mood disorders, anxiety disorders, antisocial personality disorder, psychosocial functioning, substance use
MeSH terms
Adult, Mental Disorders, Female, Follow-Up Studies, Humans, Male, Methamphetamine, Psychiatric Status Rating Scales, Severity of Illness Index, Prevalence, Diagnosis, Dual (Psychiatry), Amphetamine-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review